世界の特発性血小板減少性紫斑病（ITP）治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A15006 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、70ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、特発性血小板減少性紫斑病（ITP）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。特発性血小板減少性紫斑病（ITP）治療の種類別市場規模（コルチコステロイド、静脈内免疫グロブリン（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体アゴニスト（TPO-RA）、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・特発性血小板減少性紫斑病（ITP）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Roch、Amgen Inc、Grifols Biologicals Inc.、GlaxoSmithKline Plc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：コルチコステロイド、静脈内免疫グロブリン（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体アゴニスト（TPO-RA）、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・特発性血小板減少性紫斑病（ITP）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・特発性血小板減少性紫斑病（ITP）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・特発性血小板減少性紫斑病（ITP）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・特発性血小板減少性紫斑病（ITP）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・特発性血小板減少性紫斑病（ITP）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics size is estimated to be USD 504.9 million in 2026 from USD 446 million in 2020, with a change XX% between 2020 and 2021. The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size is expected to grow at a CAGR of 3.1% for the next five years.

Market segmentation
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonists (TPO-RA)
Others

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Roch
Amgen Inc
Grifols Biologicals Inc.
GlaxoSmithKline Plc

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, with revenue, gross margin and global market share of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics from 2019 to 2021.
Chapter 3, the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics
1.2 Classification of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Type
1.2.1 Overview: Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type in 2020
1.2.3 Corticosteroids
1.2.4 Intravenous Immunoglobulin (IVIG)
1.2.5 Anti-D Immunoglobulin
1.2.6 Thrombopoietin Receptor Agonists (TPO-RA)
1.2.7 Others
1.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Application
1.3.1 Overview: Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size & Forecast
1.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast by Region
1.5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Drivers
1.6.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Restraints
1.6.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Trends Analysis
2 Company Profiles
2.1 Roch
2.1.1 Roch Details
2.1.2 Roch Major Business
2.1.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
2.1.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roch Recent Developments and Future Plans
2.2 Amgen Inc
2.2.1 Amgen Inc Details
2.2.2 Amgen Inc Major Business
2.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
2.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Amgen Inc Recent Developments and Future Plans
2.3 Grifols Biologicals Inc.
2.3.1 Grifols Biologicals Inc. Details
2.3.2 Grifols Biologicals Inc. Major Business
2.3.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
2.3.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Grifols Biologicals Inc. Recent Developments and Future Plans
2.4 GlaxoSmithKline Plc
2.4.1 GlaxoSmithKline Plc Details
2.4.2 GlaxoSmithKline Plc Major Business
2.4.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
2.4.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 GlaxoSmithKline Plc Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Market Share
3.2.2 Top 10 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2026)
6.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2026)
6.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
6.3.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2026)
7.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2026)
7.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
7.3.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region
8.3.1 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (2016-2026)
8.3.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2026)
9.2 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2026)
9.3 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
9.3.1 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country
10.3.1 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Roch Corporate Information, Head Office, and Major Competitors
Table 7. Roch Major Business
Table 8. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
Table 9. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Amgen Inc Corporate Information, Head Office, and Major Competitors
Table 11. Amgen Inc Major Business
Table 12. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
Table 13. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Grifols Biologicals Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Grifols Biologicals Inc. Major Business
Table 16. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
Table 17. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. GlaxoSmithKline Plc Corporate Information, Head Office, and Major Competitors
Table 19. GlaxoSmithKline Plc Major Business
Table 20. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product and Solutions
Table 21. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Players (2019-2021)
Table 24. Breakdown of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 25. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Head Office, Products and Services Provided
Table 26. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Mergers & Acquisitions in the Past Five Years
Table 27. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics New Entrants and Expansion Plans
Table 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 29. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2016-2021)
Table 30. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Type (2021-2026)
Table 31. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2021)
Table 32. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Application (2021-2026)
Table 33. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 34. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 35. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 36. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 37. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 38. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 39. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 40. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 41. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 42. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 43. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 44. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 45. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 46. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 47. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 48. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 49. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 50. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 51. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 52. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 53. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 54. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 55. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 56. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 57. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 62. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Picture
Figure 2. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type in 2020
Figure 3. Corticosteroids
Figure 4. Intravenous Immunoglobulin (IVIG)
Figure 5. Anti-D Immunoglobulin
Figure 6. Thrombopoietin Receptor Agonists (TPO-RA)
Figure 7. Others
Figure 8. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application in 2020
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Others Picture
Figure 12. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region (2016-2026)
Figure 15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region in 2020
Figure 16. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Drivers
Figure 22. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Restraints
Figure 23. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Trends
Figure 24. Roch Recent Developments and Future Plans
Figure 25. Amgen Inc Recent Developments and Future Plans
Figure 26. Grifols Biologicals Inc. Recent Developments and Future Plans
Figure 27. GlaxoSmithKline Plc Recent Developments and Future Plans
Figure 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Players in 2020
Figure 29. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 30. Global Top 3 Players Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share in 2020
Figure 31. Global Top 10 Players Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share in 2020
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 33. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type in 2020
Figure 34. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share Forecast by Type (2021-2026)
Figure 35. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application in 2020
Figure 36. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share Forecast by Application (2021-2026)
Figure 37. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2016-2026)
Figure 38. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2016-2026)
Figure 39. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 40. United States Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2016-2026)
Figure 44. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2016-2026)
Figure 45. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 46. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. United Kingdom Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2016-2026)
Figure 52. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2016-2026)
Figure 53. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Region (2016-2026)
Figure 54. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2016-2026)
Figure 61. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2016-2026)
Figure 62. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 63. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Type (2016-2026)
Figure 66. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2016-2026)
Figure 67. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 68. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source

---